- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03951272
The Efficacy and Safety of Lyoplant® Onlay in Repairing Cerebral Dura Mater
May 14, 2019 updated by: B. Braun Medical International Trading Company Ltd.
A Prospective, Multi-center, Randomized, Parallel-controlled Clinical Trial Evaluating the Efficacy and Safety of Lyoplant Onlay in Repairing Cerebral Dura Mater
Objective of this clinical trial is to compare the safety and efficacy of Mianfengxing Kexishou Yingmo Bupian(Lyoplant® Onlay) and Yingmo Bupianfor dural repair.270
subjects will be enrolled for this study.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
240
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zongjie Duan
- Phone Number: +86 10 57632775
- Email: zongjie.duan@bbraun.com
Study Contact Backup
- Name: Sally Jin
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Jianmin Zhang
- Phone Number: 86 571 87784715
- Email: z2sjwk@sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Surgical patients who will receive dura mater replacement in neurosurgery;
- 18 to 75 years old, either sexes;
- Patients are ready and able to accept all visits during the trial.
- Patients are willing and able to sign Informed Consent Form (ICF) to join this clinical trial.
Related to lesions:
- Target lesion is cerebral and cerebellum dura mater defect closure, intracranial hypertension remission;
- Surgical wound classification is Class I/sterile operation and risk index category (RIC) ≤ 2.
Exclusion Criteria:
- Patients with local cerebral infection;
- Patients who suffer from systemic infection (e.g. urinary tract infection (UTI), acquired pneumonia) or any infection sign at surgical site before the surgery, with body temperature > 38.5℃, positive result in blood culture, and/or positive result in chest X-ray examination;
- Patients who are allergic to the equipment components (Such as, by asking the patient's history of allergies, doctors understand whether the patient is allergic to proteins of bovine origin or implant or not);
- There is metal implant in patient's brain and the implant will interfere the assessment on devices or surgery recovery;
- Patients in gestation period or lactation period or planned to be pregnant during the trial;
- Patients with more than 1 separated dura mater defects;
- Patients with previous neurosurgery history at the same anatomic site;
- Patients with cranial open trauma;
- Patients requiring the use of dura adhesive or sealant;
- Patients whose expected survival time is less than 12 months;
- Patients received chemotherapy and/or radiotherapy within 3 months before the surgery;
- Patients who had diagnosed as malignant tumor of other parts except brain tumor, uncontrolled diabetes, septicemia, systemic collagen diseases clinically;
- Patients who had been accompanied with liver and renal dysfunction, with ALT and AST>1.5 times the upper limit of the standard, total bilirubin level > 2.5 mg/dl, creatinine level > 2.0 mg/dl;
- Patients with significant clinical coagulation disorders, Activated partial thromboplastin time (APTT) was 3 times more than ULN (upper limit of normal), international normalized ratio (INR) is ≥ 1.7, or under the treatment of Warfarin or Coumadin;
- Patients with immune system damage or autoimmune diseases (white blood cell (WBC) count is < 4000/uL or >20,000/uL);
- Patients whose serological test results show that people with hepatitis B, hepatitis C, syphilis, AIDS and other infectious diseases during screening period;
- Patients in whom subdural drainage for more than 2 days must be performed in the surgery;
- Patients who are participating other clinical trials of investigational devices/drugs;
- Patients who are not suitable for this study as determined by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lyoplant® Onlay
All the model including 2.5cm×2.5cm,
5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm
will be used in this study
|
Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
|
Active Comparator: DURAFORM™ Dural Graft Implant
All the model including 2.54cm×2.54cm,5.08cm×5.08cm,
2.54cm×7.62cm,
7.62cm×7.62cm,10.16cm×12.70cm
will be used in this study
|
Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days
Time Frame: 90days
|
Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days after the surgery (Confirmed by radiological image evaluation and physical examination on surgical site).
Each patient firstly undergoes an initial CT and if necessary, MRI will be used to further examine the volume of CSF leakage.
|
90days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2018
Primary Completion (Anticipated)
August 30, 2019
Study Completion (Anticipated)
August 30, 2019
Study Registration Dates
First Submitted
May 14, 2019
First Submitted That Met QC Criteria
May 14, 2019
First Posted (Actual)
May 15, 2019
Study Record Updates
Last Update Posted (Actual)
May 15, 2019
Last Update Submitted That Met QC Criteria
May 14, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- AAG-G-H-1715
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Replacement and Extension of Connective Tissue Structure in Neurosurgery
-
State University of New York - Upstate Medical...WithdrawnAssess Motion in Flexion/Extension and Lateral Bending of the Lumbar Vertebrae in Vivo Following Motion Sparing Surgery Using Radiostereometric Analysis (RSA.)United States
-
Region SkaneJRI Orthopaedics LtdActive, not recruitingHip Replacement in Osteoarthritis PatientsSweden
-
Hellenic Breast Surgeons SocietyCompletedBreast Cancer | Other Disorders of Bone Density and StructureGreece
-
Ottawa Hospital Research InstituteUnknownArthroplasty, Replacement, Hip | Hip Replacement, TotalCanada
-
Dr. Ho Ki WaiCompletedKnee Arthroplasty | Knee Arthroplasty, Total | Total Knee Replacement | Osteoarthritis Of Knee | Knee Replacement, Total | Replacement, Total Knee | Health-Related Quality Of Life | Life Quality
-
Assiut UniversityRecruitingFollow up of Moderate Aortic Regurge After Rheumatic Mitral Valve ReplacementEgypt
-
Hacettepe UniversityCompletedTo Evaluate the Efficacy of Platelet-rich Fibrin in Papilla Reconstruction | To Evaluate the Efficacy of Connective Tissue Graft in Papilla ReconstructionTurkey
-
Southwest Hospital, ChinaUnknownArthritis, Rheumatoid | Arthroplasty, Replacement, Knee | Recovery of FunctionChina
-
Global Orthopaedic TechnologyLSS Surgical Pty LtdUnknownOsteoarthritis of the Knee | Total Knee ReplacementAustralia
-
MaterialiseEnrolling by invitationOsteoarthritis of the Shoulder | Arthroplasty, Replacement, Shoulder | Glenoid CavityBelgium, Netherlands
Clinical Trials on Lyoplant® Onlay/DURAFORM™ Dural Graft Implant
-
Synthes USA HQ, Inc.Completed
-
Polish Hernia Study GroupTerminatedHernia, Abdominal | Hernia,VentralPoland